Osiris Clinical Trial Results Challenge FDA Protocol
Osiris Therapeutics reports that its adult stem cell product, Prochymal, has performed well in a subset of patients in a clinical trial, the FDA calls the trial a "failure" because the FDA does not recognize patient subsets.